Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

18 trials with published results (6%)

Research Maturity

128 completed trials (45% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.7%

16 terminated out of 282 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

5%

14 trials in Phase 3/4

Results Transparency

14%

18 of 128 completed with results

Key Signals

18 with results89% success16 terminated

Data Visualizations

Phase Distribution

161Total
Not Applicable (97)
Early P 1 (2)
P 1 (17)
P 2 (31)
P 3 (9)
P 4 (5)

Trial Status

Completed128
Unknown74
Recruiting34
Terminated16
Not Yet Recruiting14
Withdrawn9

Trial Success Rate

88.9%

Benchmark: 86.6%

Based on 128 completed trials

Clinical Trials (282)

Showing 20 of 20 trials
NCT04401475Phase 2Terminated

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

NCT07836153Not Yet Recruiting

Mechanical Power and Mortality in Mechanically Ventilated Adults

NCT07823296Not Yet RecruitingPrimary

Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)

NCT07807046Not ApplicableRecruitingPrimary

TwichView-guided Atricurium Dose Adjustment Trial

NCT06737432Not ApplicableActive Not Recruiting

Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms.

NCT06808438CompletedPrimary

Incremental and Decremental PEEP Titration by Diverse Strategies in Subjects With ARDS: A Prospective Physiological Study

NCT07445061Completed

Machine Learning Prediction of Mortality After Prone Positioning in ARDS

NCT04367077Phase 2TerminatedPrimary

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

NCT06701682Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

NCT06703073Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06701669Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701656Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

NCT07634419Not ApplicableNot Yet Recruiting

Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress

NCT07664358Recruiting

Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury

NCT04365101Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT06511622CompletedPrimary

Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure

NCT04401111Active Not Recruiting

One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)

NCT04371029Not ApplicableCompletedPrimary

Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS

NCT05137795Phase 3Withdrawn

Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19

NCT04402879Not ApplicableCompleted

CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals

Scroll to load more

Research Network

Activity Timeline